Your Source for BioScience Venture Capital Data
  • SEARCH THE OnBioVC DATABASE:

  • OnBioVC NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • Photobucket

  • FDA Registered Contract Manufacturer

Kiadis Pharma (Netherlands), a clinical-stage biopharmaceutical company developing treatments for blood cancers, closed a $12.8M Series D financing. Participants include Life Sciences Partners, DFJ-Esprit, Alta Partners, Quest for Growth and NOM.

Innovent Biologics (China), a clinical stage biotechnology company focused on the development of monoclonal antibodies targeting various diseases, closed a $25M Series B financing. Participants include Lilly Asia Ventures, Fidelity Biosciences and Fidelity Growth Partners Asia.

MabVax Therapeutics (San Diego, CA), a clinical-stage biotechnology company focused on cancer immunotherapies, closed a $5.3M Series B financing. Participants include Numoda Capital Innovations, Burrill & Co. and RTP Venture Fund. Collective IP | The World’s Largest Technology Transfer Office Marketplace Providing Unrivaled Comprehensive and Accurate Access to Humankinds Most Valuable and Transformative Assets Receive [...]

Epic Sciences (San Diego, CA), a preclinical-stage biotechnology company focused on cancer diagnostics, closed a $13M Series B financing. Participants include Domain Associates, Roche Venture Fund, and Pfizer Venture Investments. Collective IP | The World’s Largest Technology Transfer Office Marketplace Providing Unrivaled Comprehensive and Accurate Access to Humankinds Most Valuable and Transformative Assets Receive Collective [...]

Metamark Genetics (Cambridge, MA), a preclinical-stage molecular diagnostics company focused on cancer, closed a $13M Series B financing. Participants were not identified. Collective IP | The World’s Largest Technology Transfer Office Marketplace Providing Unrivaled Comprehensive and Accurate Access to Humankinds Most Valuable and Transformative Assets Receive Collective IP Account Access HERE

Ambit Biosciences (San Diego, CA), a clinical-stage biotechnology company focused on kinase-based therapeutics for cancer, closed a $25M Series E financing. Participants include OrbiMed Advisors, Aisling Capital, Apposite Healthcare, Roche Ventures, GrowthWorks, MedImmune Ventures, Forward Ventures, GIMV, and Radius Ventures. Collective IP | The World’s Largest Technology Transfer Office Marketplace Providing Unrivaled Comprehensive and Accurate [...]

Alethia Biotherapeutics (Canada), a preclinical-stage biotechnology company focused on bone degredation, closed a $4.7M Series B financing. Participants include AgeChem Venture Fund, BDC Venture Capital and GO Capital. Collective IP | The World’s Largest Technology Transfer Office Marketplace Providing Unrivaled Comprehensive and Accurate Access to Humankinds Most Valuable and Transformative Assets Receive Collective IP Account [...]

Gliknik (Baltimore, MD), a clinical-stage biotechnology company focused on treatments for cancer and autoimmune diseases, closed a $4.9M Series B financing. Participants include Baxter Ventures. Collective IP | The Most Comprehensive and Accurate View of Global Innovation and Organization of the International Technology Transfer Office Ecosystem Request Collective IP Account Access HERE

Principia Biopharma (San Francisco, CA), a biopharmaceutical company focused on immunology, autoimmune diseases and oncology, closed a $12.5M Series A financing, bringing the total round to $36.6M. Participants include New Leaf Venture Partners, OrbiMed Advisors, Morgenthaler Ventures, SR One and Mission Bay Capital. Collective IP | The Most Comprehensive and Accurate View of Global Innovation [...]

Pharma Two B (Israel), a pre-clinical stage pharmaceutical company focused on developing Fixed-Dose-combinations of approved drugs for Parkinson’s disease and Cancer, closed a $8 million Series B financing. Participants include JK&B Capital and Crossroad. ___________ Collective IP the Most Comprehensive and Accurate View of Global Innovation and Organization of the International Technology Transfer Office Ecosystem

Aragon Pharmaceuticals (San Diego, CA) a clinical-stage small molecule company focused on the treatment of hormone-resistant cancers, with an intital focuse on prostate and breast cancer, closed a $42M Series C financing. Participants include Aisling Capital, OrbiMed, Column Group and Topspin Partners. Note: Closing out 1Q deals. Thanx for your patience as we play catch-up.

ViewRay (Oakwood Village, OH) a clinical-stage medical device company focused on MRI-guided radiation therapy system for the treatment of various cancers, closed a $26.3M Series C financing, bringing the total round to $45M. Participants include Aisling Capital, Fidelity Biosciences, Kearny Venture Partners, OrbiMed and Siemens Venture Capital.

ImaginAb (Inglewood, CA) a clinical-stage biopharmaceutical company focused on re-engineered therapeutic antibody fragments against biologic targets for diagnostic imaging with Positron Emission Tomography scans for management of cancer and autoimmune disease, closed a $12.5M Series B financing. Participants include Novartis Venture Funds, Merieux Developpement, Nextech Invest, Cycad Group and Momentum Biosciences.

« Previous Entries  Next Page »

to top of page...